{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:37:45Z","timestamp":1790800665605,"version":"4.1.0"},"reference-count":119,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1194462"],"award-info":[{"award-number":["APP1194462"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Schistosomiasis, caused by human trematode blood flukes (schistosomes), remains one of the most prevalent and serious of the neglected tropical parasitic diseases. Currently, treatment of schistosomiasis relies solely on a single drug, the anthelmintic praziquantel, and with increased usage in mass drug administration control programs for the disease, the specter of drug resistance developing is a constant threat. Vaccination is recognized as one of the most sustainable options for the control of any pathogen, but despite the discovery and reporting of numerous potentially promising schistosome vaccine antigens, to date, no schistosomiasis vaccine for human or animal deployment is available. This is despite the fact that Science ranked such an intervention as one of the top 10 vaccines that need to be urgently developed to improve public health globally. This review summarizes current progress of schistosomiasis vaccines under clinical development and advocates the urgent need for the establishment of a revolutionary and effective anti-schistosome vaccine pipeline utilizing cutting-edge technologies (including developing mRNA vaccines and exploiting CRISPR-based technologies) to provide novel insight into future vaccine discovery, design, manufacture and deployment.<\/jats:p>","DOI":"10.3390\/ijms23042255","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T08:18:05Z","timestamp":1645431485000},"page":"2255","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects"],"prefix":"10.3390","volume":"23","author":[{"given":"Adebayo J.","family":"Molehin","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, College of Graduate Studies, Midwestern University, Glendale, AZ 85308, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-1449","authenticated-orcid":false,"given":"Donald P.","family":"McManus","sequence":"additional","affiliation":[{"name":"Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-7793","authenticated-orcid":false,"given":"Hong","family":"You","sequence":"additional","affiliation":[{"name":"Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"i15","DOI":"10.1093\/inthealth\/ihw002","article-title":"Leaving no one behind: A neglected tropical disease indicator and tracers for the Sustainable Development Goals","volume":"8","author":"Fitzpatrick","year":"2016","journal-title":"Int. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-018-0013-8","article-title":"Schistosomiasis","volume":"4","author":"McManus","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2149\/tmh.2014-S04","article-title":"Morbidity control of schistosomiasis by mass drug administration: How can we do it best and what will it take to move on to elimination?","volume":"42","author":"Colley","year":"2014","journal-title":"Trop. Med. Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/pim.12087","article-title":"Immunology of human schistosomiasis","volume":"36","author":"Colley","year":"2014","journal-title":"Parasite Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","article-title":"Human schistosomiasis","volume":"383","author":"Colley","year":"2014","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.actatropica.2009.11.012","article-title":"Parasites and poverty: The case of schistosomiasis","volume":"113","author":"King","year":"2010","journal-title":"Acta Trop."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1093\/cid\/ciy001","article-title":"Are We on Our Way to Achieving the 2020 Goals for Schistosomiasis Morbidity Control Using Current World Health Organization Guidelines?","volume":"66","author":"Toor","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"d2651","DOI":"10.1136\/bmj.d2651","article-title":"Diagnosis and management of schistosomiasis","volume":"342","author":"Gray","year":"2011","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13071-015-0766-9","article-title":"The roles of water, sanitation and hygiene in reducing schistosomiasis: A review","volume":"8","author":"Grimes","year":"2015","journal-title":"Parasit. Vectors"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40249-017-0256-8","article-title":"Moving from control to elimination of schistosomiasis in sub-Saharan Africa: Time to change and adapt strategies","volume":"6","author":"Rollinson","year":"2017","journal-title":"Infect. Dis. Poverty"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1812165","article-title":"Schistosomiasis-Assessing Progress toward the 2020 and 2025 Global Goals","volume":"381","author":"Deol","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/S0140-6736(14)61417-3","article-title":"An audacious goal: The elimination of schistosomiasis in our lifetime through mass drug administration","volume":"385","author":"Ross","year":"2015","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"F1000Faculty Rev-1157","DOI":"10.12688\/f1000research.6826.1","article-title":"Early lessons from schistosomiasis mass drug administration programs","volume":"4","author":"Secor","year":"2015","journal-title":"F1000Research"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"622809","DOI":"10.3389\/fpubh.2021.622809","article-title":"Rethinking the Top-Down Approach to Schistosomiasis Control and Elimination in Sub-Saharan Africa","volume":"9","author":"Onasanya","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1473-3099(10)70099-2","article-title":"Schistosomiasis elimination: Lessons from the past guide the future","volume":"10","author":"Gray","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pt.2003.11.010","article-title":"Schistosomiasis control: Keep taking the tablets","volume":"20","author":"Hagan","year":"2004","journal-title":"Trends Parasitol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1017\/S0031182016001190","article-title":"Hybridizations within the Genus Schistosoma: Implications for evolution, epidemiology and control","volume":"144","author":"Leger","year":"2017","journal-title":"Parasitology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s13071-019-3635-0","article-title":"Persistent establishment of a tropical disease in Europe: The preadaptation of schistosomes to overwinter","volume":"12","author":"Mulero","year":"2019","journal-title":"Parasit. Vectors"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1126\/science.361.6405.832","article-title":"Hybridization may give some parasites a leg up","volume":"361","author":"Pennisi","year":"2018","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20130433","DOI":"10.1098\/rstb.2013.0433","article-title":"The contribution of vaccination to global health: Past, present and future","volume":"369","author":"Greenwood","year":"2014","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12929-020-0621-y","article-title":"Schistosomiasis vaccine development: Update on human clinical trials","volume":"27","author":"Molehin","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/14760584.2016.1131127","article-title":"Development of a schistosomiasis vaccine","volume":"15","author":"Molehin","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13071-017-2227-0","article-title":"Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities","volume":"10","author":"Stylianou","year":"2017","journal-title":"Parasit. Vectors"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0001-706X(02)00017-7","article-title":"Mathematical modelling of schistosomiasis japonica: Comparison of control strategies in the People\u2019s Republic of China","volume":"82","author":"Williams","year":"2002","journal-title":"Acta Trop."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00281-020-00789-x","article-title":"Schistosomiasis-from immunopathology to vaccines","volume":"42","author":"McManus","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1473-3099(20)30254-1","article-title":"Sensitive diagnostic tools and targeted drug administration strategies are needed to eliminate schistosomiasis","volume":"20","author":"Amoah","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.vaccine.2015.12.032","article-title":"Workshop report: Schistosomiasis vaccine clinical development and product characteristics","volume":"34","author":"Mo","year":"2016","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pt.2016.10.010","article-title":"Sm-p80-Based Schistosomiasis Vaccine: Preparation for Human Clinical Trials","volume":"33","author":"Siddiqui","year":"2017","journal-title":"Trends Parasitol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13071-016-1369-9","article-title":"Do schistosome vaccine trials in mice have an intrinsic flaw that generates spurious protection data?","volume":"9","author":"Wilson","year":"2016","journal-title":"Parasit. Vectors"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/vaccines2030654","article-title":"Schistosome Vaccine Adjuvants in Preclinical and Clinical Research","volume":"2","author":"Stephenson","year":"2014","journal-title":"Vaccines"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2015.00213","article-title":"Of monkeys and men: Immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates","volume":"6","author":"Pearson","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3389\/fimmu.2020.01246","article-title":"Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer Protection in vivo and in vitro From Schistosoma mansoni and Identification of Putative Correlative Markers of Protection","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"635985","DOI":"10.3389\/fimmu.2021.635985","article-title":"Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings","volume":"12","author":"Driciru","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_34","first-page":"119","article-title":"Current Understanding of Immunity against Schistosomiasis: Impact on Vaccine and Drug Development","volume":"11","author":"Molehin","year":"2020","journal-title":"Res. Rep. Trop. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0264-410X(98)00202-3","article-title":"Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge","volume":"17","author":"Boulanger","year":"1999","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Riveau, G., Schacht, A.M., Dompnier, J.P., Deplanque, D., Seck, M., Waucquier, N., Senghor, S., Delcroix-Genete, D., Hermann, E., and Idris-Khodja, N. (2018). Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006968"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.vaccine.2015.10.027","article-title":"Schistosomiasis vaccine candidate Sm14\/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults","volume":"34","author":"Coler","year":"2016","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1016\/j.vaccine.2019.08.075","article-title":"A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area","volume":"37","author":"Keitel","year":"2019","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/infdis\/jiy275","article-title":"Establishing the Production of Male Schistosoma mansoni Cercariae for a Controlled Human Infection Model","volume":"218","author":"Janse","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41591-020-0759-x","article-title":"A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics","volume":"26","author":"Langenberg","year":"2020","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/pmic.200500368","article-title":"The tegument surface membranes of the human blood parasite Schistosoma mansoni: A proteomic analysis after differential extraction","volume":"6","author":"Braschi","year":"2006","journal-title":"Proteomics"},{"key":"ref_43","first-page":"3641","article-title":"Tetraspanins at a glance","volume":"127","author":"Charrin","year":"2014","journal-title":"J. Cell Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nm1430","article-title":"Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis","volume":"12","author":"Tran","year":"2006","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Pearson, M.S., Pickering, D.A., McSorley, H.J., Bethony, J.M., Tribolet, L., Dougall, A.M., Hotez, P.J., and Loukas, A. (2012). Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001564"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/pim.12118","article-title":"A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice","volume":"36","author":"Pinheiro","year":"2014","journal-title":"Parasite Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2337\/diabetes.53.2007.S12","article-title":"Structure, activation, and biology of calpain","volume":"53","author":"Suzuki","year":"2004","journal-title":"Diabetes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1007\/s00436-017-5634-4","article-title":"Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80\/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium","volume":"116","author":"Molehin","year":"2017","journal-title":"Parasitol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0925-4439(93)90087-H","article-title":"Characterization of Ca2+-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni","volume":"1181","author":"Siddiqui","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/S0264-410X(03)00159-2","article-title":"Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation","volume":"21","author":"Siddiqui","year":"2003","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.vaccine.2009.02.096","article-title":"Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model","volume":"27","author":"Ahmad","year":"2009","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-3024.2008.01091.x","article-title":"Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni","volume":"31","author":"Ahmad","year":"2009","journal-title":"Parasite Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.vaccine.2013.12.057","article-title":"Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons","volume":"32","author":"Karmakar","year":"2014","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.13942","article-title":"Sm-p80-based schistosomiasis vaccine: Double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy","volume":"1425","author":"Zhang","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/infdis\/jir545","article-title":"Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic","volume":"204","author":"Ahmad","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gaze, S., Driguez, P., Pearson, M.S., Mendes, T., Doolan, D.L., Trieu, A., McManus, D.P., Gobert, G.N., Periago, M.V., and Correa Oliveira, R. (2014). An immunomics approach to schistosome antigen discovery: Antibody signatures of naturally resistant and chronically infected individuals from endemic areas. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004033"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"719369","DOI":"10.3389\/fitd.2021.719369","article-title":"Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis","volume":"2","author":"Panzner","year":"2021","journal-title":"Front. Trop. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.actatropica.2008.09.002","article-title":"The biotechnology-value chain: Development of Sm14 as a schistosomiasis vaccine","volume":"108","author":"Tendler","year":"2008","journal-title":"Acta Trop."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.micinf.2004.10.012","article-title":"Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis","volume":"7","author":"Fonseca","year":"2005","journal-title":"Microbes Infect."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.actatropica.2008.03.003","article-title":"Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice","volume":"106","author":"Garcia","year":"2008","journal-title":"Acta Trop."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1073\/pnas.93.1.269","article-title":"A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine","volume":"93","author":"Tendler","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0169-4758(89)90185-3","article-title":"Glutathione S-transferases-potential components of anti-schistosome vaccines?","volume":"5","author":"Mitchell","year":"1989","journal-title":"Parasitol Today"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1002\/eji.200324143","article-title":"Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion","volume":"33","author":"Herve","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.str.2005.06.007","article-title":"Insights into the catalytic mechanism of glutathione S-transferase: The lesson from Schistosoma haematobium","volume":"13","author":"Angelucci","year":"2005","journal-title":"Structure"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1128\/IAI.70.2.601-605.2002","article-title":"Functional specific binding of testosterone to Schistosoma haematobium 28-kilodalton glutathione S-transferase","volume":"70","author":"Remoue","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Riveau, G., Deplanque, D., Remoue, F., Schacht, A.M., Vodougnon, H., Capron, M., Thiry, M., Martial, J., Libersa, C., and Capron, A. (2012). Safety and immunogenicity of rSh28GST antigen in humans: Phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001704"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/14760584.3.3.315","article-title":"Current status and future prospects for a vaccine against schistosomiasis","volume":"3","author":"Lebens","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00436-010-1855-5","article-title":"Murine schistosomiasis as a model for human schistosomiasis mansoni: Similarities and discrepancies","volume":"107","author":"Hassan","year":"2010","journal-title":"Parasitol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ijpara.2009.06.006","article-title":"Transcriptional profiles of adult male and female Schistosoma japonicum in response to insulin reveal increased expression of genes involved in growth and development","volume":"39","author":"You","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"You, H., McManus, D.P., Hu, W., Smout, M.J., Brindley, P.J., and Gobert, G.N. (2013). Transcriptional responses of in vivo praziquantel exposure in schistosomes identifies a functional role for calcium signalling pathway member CamKII. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003254"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng.1065","article-title":"Whole-genome sequence of Schistosoma haematobium","volume":"44","author":"Young","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature08160","article-title":"The genome of the blood fluke Schistosoma mansoni","volume":"460","author":"Berriman","year":"2009","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"111322","DOI":"10.1016\/j.molbiopara.2020.111322","article-title":"A comparative proteomics analysis of the egg secretions of three major schistosome species","volume":"240","author":"Carson","year":"2020","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-0716-0635-3_8","article-title":"Proteomic Analysis of Schistosoma mansoni Tegumental Proteins","volume":"2151","author":"Pearson","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Sotillo, J., Pearson, M.S., Becker, L., Mekonnen, G.G., Amoah, A.S., van Dam, G., Corstjens, P., Murray, J., Mduluza, T., and Mutapi, F. (2019). In-depth proteomic characterization of Schistosoma haematobium: Towards the development of new tools for elimination. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007362"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1017\/S0031182012000339","article-title":"Proteomics at the schistosome-mammalian host interface: Any prospects for diagnostics or vaccines?","volume":"139","author":"Wilson","year":"2012","journal-title":"Parasitology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13071-019-3403-1","article-title":"Qualitative and quantitative proteomic analyses of Schistosoma japonicum eggs and egg-derived secretory-excretory proteins","volume":"12","author":"Potriquet","year":"2019","journal-title":"Parasit. Vectors"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"663041","DOI":"10.3389\/fimmu.2021.663041","article-title":"Immunomics-guided antigen discovery for praziquantel-induced vaccination in Urogenital human Schistosomiasis","volume":"12","author":"Pearson","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-3024.2011.01330.x","article-title":"Novel immunomic technologies for schistosome vaccine development","volume":"34","author":"McWilliam","year":"2012","journal-title":"Parasite Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"624613","DOI":"10.3389\/fimmu.2020.624613","article-title":"Epitope mapping of exposed tegument and alimentary tract proteins identifies putative antigenic targets of the attenuated schistosome vaccine","volume":"11","author":"Farias","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/jim-2018-000786","article-title":"Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models","volume":"66","author":"Zhang","year":"2018","journal-title":"J. Investig. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1074\/mcp.M700004-MCP200","article-title":"Glycomics analysis of Schistosoma mansoni egg and cercarial secretions","volume":"6","author":"Curwen","year":"2007","journal-title":"Mol. Cell. Proteom."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.exppara.2007.06.003","article-title":"Glycomics-driven discoveries in schistosome research","volume":"117","author":"Hokke","year":"2007","journal-title":"Exp. Parasitol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijpara.2020.05.005","article-title":"Uptake of Schistosoma mansoni extracellular vesicles by human endothelial and monocytic cell lines and impact on vascular endothelial cell gene expression","volume":"50","author":"Kifle","year":"2020","journal-title":"Int. J. Parasitol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"111264","DOI":"10.1016\/j.molbiopara.2020.111264","article-title":"Proteomic analysis of two populations of Schistosoma mansoni-derived extracellular vesicles: 15k pellet and 120k pellet vesicles","volume":"236","author":"Kifle","year":"2020","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Mekonnen, G.G., Tedla, B.A., Pickering, D., Becker, L., Wang, L., Zhan, B., Bottazzi, M.E., Loukas, A., Sotillo, J., and Pearson, M.S. (2020). Schistosoma haematobium Extracellular Vesicle Proteins Confer Protection in a Heterologous Model of Schistosomiasis. Vaccines, 8.","DOI":"10.1101\/2020.06.24.168773"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/bs.apar.2015.02.002","article-title":"Prospects for vector-based gene silencing to explore immunobiological features of Schistosoma mansoni","volume":"88","author":"Hagen","year":"2015","journal-title":"Adv. Parasitol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-4939-1438-8_8","article-title":"Gene suppression in schistosomes using RNAi","volume":"1201","author":"Skelly","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.pt.2015.03.009","article-title":"Knocking down schistosomes-promise for lentiviral transduction in parasites","volume":"31","author":"Hagen","year":"2015","journal-title":"Trends Parasitol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature08140","article-title":"The Schistosoma japonicum genome reveals features of host-parasite interplay","volume":"460","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1126\/science.abb7699","article-title":"Large-scale RNAi screening uncovers therapeutic targets in the parasite Schistosoma mansoni","volume":"369","author":"Wang","year":"2020","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10565-019-09489-1","article-title":"CRISPR-Cas12 and Cas13: The lesser known siblings of CRISPR-Cas9","volume":"35","author":"Yan","year":"2019","journal-title":"Cell Biol. Toxicol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e41337","DOI":"10.7554\/eLife.41337","article-title":"Programmed genome editing of the omega-1 ribonuclease of the blood fluke, Schistosoma mansoni","volume":"8","author":"Ittiprasert","year":"2019","journal-title":"Elife"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e21205","DOI":"10.1096\/fj.202001745RR","article-title":"CRISPR\/Cas9-mediated genome editing of Schistosoma mansoni acetylcholinesterase","volume":"35","author":"You","year":"2021","journal-title":"FASEB J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"178","DOI":"10.12688\/wellcomeopenres.16031.1","article-title":"Large CRISPR-Cas-induced deletions in the oxamniquine resistance locus of the human parasite Schistosoma mansoni","volume":"5","author":"Sankaranarayanan","year":"2020","journal-title":"Wellcome Open Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e2000185","DOI":"10.1002\/bies.202000185","article-title":"CRISPR\/Cas9: A new tool for the study and control of helminth parasites","volume":"43","author":"Du","year":"2021","journal-title":"Bioessays"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"You, H., Harvie, M., Du, X., Rivera, V., Zhang, P., and McManus, D.P. (2018). Protective immune responses generated in a murine model following immunization with recombinant Schistosoma japonicum insulin receptor. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103088"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exppara.2014.07.010","article-title":"Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection","volume":"145","author":"Ewaisha","year":"2014","journal-title":"Exp. Parasitol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijbiomac.2019.08.259","article-title":"Development of a conserved chimeric vaccine based on helper T-cell and CTL epitopes for induction of strong immune response against Schistosoma mansoni using immunoinformatics approaches","volume":"141","author":"Rahmani","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"621706","DOI":"10.3389\/fimmu.2021.621706","article-title":"Immunoinformatics design of multi-epitope peptide-based vaccine against Schistosoma mansoni using transmembrane proteins as a target","volume":"12","author":"Sanches","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-3024.2009.01181.x","article-title":"Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse","volume":"32","author":"Zhang","year":"2010","journal-title":"Parasite Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fimmu.2019.00284","article-title":"Prime-boost vaccine regimen for SjTPI and SjC23 schistosome vaccines, increases efficacy in water buffalo in a field trial in China","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1016\/j.vaccine.2008.04.080","article-title":"DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo","volume":"26","author":"Li","year":"2008","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1128\/IAI.69.9.5352-5362.2001","article-title":"Cellular and humoral immune responses and protection against schistosomes induced by a radiation-attenuated vaccine in chimpanzees","volume":"69","author":"Eberl","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-3024.2005.00783.x","article-title":"Resistance to re-infection after exposure to normal and attenuated schistosome parasites in the baboon model","volume":"27","author":"Kariuki","year":"2005","journal-title":"Parasite Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.exppara.2006.07.004","article-title":"Serum cytokines of the 20 Krad-irradiated S. mansoni cercariae vaccinated, primary and superinfected Cercopethicus aethiops aethiops","volume":"115","author":"Torben","year":"2007","journal-title":"Exp. Parasitol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00436-009-1646-z","article-title":"Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine","volume":"105","author":"Ahmad","year":"2009","journal-title":"Parasitol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1016\/j.ijid.2010.02.2266","article-title":"Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice","volume":"14","author":"Ahmad","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.actatropica.2011.01.010","article-title":"Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum)","volume":"118","author":"Zhang","year":"2011","journal-title":"Acta Trop."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA Vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zeng, C., Zhang, C., Walker, P.G., and Dong, Y. (2020). Formulation and delivery technologies for mRNA vaccines. Current Topics in Microbiology and Immunology, Springer.","DOI":"10.1007\/82_2020_217"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41467-018-05041-7","article-title":"Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection","volume":"9","author":"Siu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3389\/fimmu.2018.02420","article-title":"Heterologous immunization with defined RNA and subunit vaccines enhances T cell responses that protect against Leishmania donovani","volume":"9","author":"Duthie","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fmicb.2017.00605","article-title":"Induction of protective immunity against Toxoplasma gondii in mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in Lipid Nanoparticle (LNP)","volume":"8","author":"Luo","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Cagigi, A., and Lore, K. (2021). Immune Responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines, 9.","DOI":"10.3390\/vaccines9010061"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-3024.2005.00764.x","article-title":"Immunity induced by the radiation-attenuated schistosome vaccine","volume":"27","author":"Hewitson","year":"2005","journal-title":"Parasite Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"eabj9827","DOI":"10.1126\/scitranslmed.abj9827","article-title":"mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent","volume":"13","author":"Sajid","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"McManus, D.P. (2021). The search for a schistosomiasis vaccine: Australia\u2032s contribution. Vaccines, 9.","DOI":"10.3390\/vaccines9080872"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:22:07Z","timestamp":1760134927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":119,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23042255"],"URL":"https:\/\/doi.org\/10.3390\/ijms23042255","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]}}}